VSTM Q4 2025 Earnings — Verastem, Inc. Revenue & Financial Results | Market Cap Arena

VSTMVerastem, Inc.

$388M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M

Gross Profit

$15M83.5% margin

Operating Income

-$41M-236.5% margin

Net Income

-$33M-187.7% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

+56.0%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$246M

Total Liabilities

$189M

Stockholders' Equity

$57M

Cash & Equivalents

$205M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$0	—
Gross Profit	$15M	$0	—
Operating Income	-$41M	-$32M	-31.3%
Net Income	-$33M	-$65M	+49.0%

Revenue Segments

Government rebates and other incentives

$2M78%

Trade discounts and allowances

$392,00015%

Returns

$185,0007%